Understanding hemophilia

What is hemophilia?

Hemophilia is a rare inherited bleeding disorder. People with hemophilia have blood that does not clot properly, so it is difficult for their body to stop bleeding after an injury.

Here is the key point: People with hemophilia do not bleed faster than others—they bleed longer. A small cut may look fine at first, but bleeding continues much longer than usual. Minor abrasions that stop within minutes for most people can bleed for hours in a person with hemophilia.

The difference between normal bleeding and hemophilia bleeding is especially dangerous when it happens inside the body. Internal bleeding—into joints, muscles, or organs—can cause serious damage without prompt treatment.

The good news is that with proper treatment and care, people with hemophilia can live normal, full lives.

How normal blood clotting works

To understand hemophilia, it is helpful to know how clotting normally works.

The clotting process

When an injury occurs:

1. First response: Platelets quickly move to the injury site and stick together to form a temporary plug
2. Chemical cascade: The body activates special proteins called clotting factors that act like a chemical assembly line
3. Network formation: Clotting factors create a mesh‑like substance called fibrin, which strengthens and locks in the temporary plug
4. Final clot: All of these components together form a stable clot that seals the wound and stops bleeding

What happens in hemophilia

In hemophilia, one or more clotting factors are missing or present at very low levels. This breaks the “assembly line.” Without the necessary factors, the body cannot complete clotting properly.

Result: bleeding that does not stop, or bleeding that starts without an obvious injury (so‑called spontaneous bleeding).

Types of hemophilia

Hemophilia A

The most common type, affecting about 80% of people with hemophilia. It is caused by a low level or complete absence of clotting factor VIII.

Hemophilia A is caused by a mutation in the F8 gene located on the X chromosome. There are many different mutations, each with its own characteristics.

Hemophilia B

The second most common type. Hemophilia B affects about 20% of people with hemophilia and is caused by a low level or absence of factor IX.

Like hemophilia A, it results from a mutation in a gene on the X chromosome (the F9 gene).

How severity is measured

Both types are classified by how much clotting factor is present in the blood:

Severe hemophilia: Less than 1% of normal clotting factor levels. People with severe hemophilia have a high risk of spontaneous bleeding and need regular preventive treatment.

Moderate hemophilia: Between 1–5% of normal levels. Bleeding usually occurs after injury or surgery, though spontaneous bleeding can occur.

Mild hemophilia: Between 5–40% of normal levels. Bleeding typically occurs only after surgery, dental work, or major injury.

How hemophilia develops

Hemophilia is inherited

Hemophilia is a hereditary genetic disorder passed down in families. It cannot be “caught” from another person, and it is not caused by lifestyle choices.

X‑linked inheritance: why it mainly affects males

It is important to know that hemophilia genes are located on the X chromosome.

Men have one X and one Y chromosome (XY). If their single X chromosome carries the hemophilia gene, hemophilia manifests. There is no “backup” copy.

Women have two X chromosomes (XX). If one X carries the hemophilia gene, the other usually contains a healthy copy that compensates. That is why women are often “carriers”—they carry the gene but usually have no symptoms.

This is why hemophilia primarily affects males (boys and men), while women are typically carriers who can pass the gene to children.

How it is inherited

A mother who is a carrier (one healthy X and one X with the hemophilia gene) has a 50% chance in each pregnancy to:

• pass the hemophilia gene to a son (the son will have hemophilia)
• pass the hemophilia gene to a daughter (the daughter will be a carrier)
• pass a healthy X to a son (the son will not have hemophilia)
• pass a healthy X to a daughter (the daughter will not be a carrier)

Women and hemophilia

Although most carriers have no symptoms, some do. Symptoms can appear if:

• there is uneven X‑inactivation, so more cells with the hemophilia gene are active
• clotting factor levels are moderately reduced

Carriers with symptoms often experience heavy menstrual bleeding and may need treatment before surgery or childbirth.

New cases without family history

About one‑third of hemophilia cases occur in families with no previous history. This happens when a new mutation appears in a child—essentially a genetic “accident” that was not inherited from the parents.

Acquired hemophilia

Rarely, hemophilia can develop later in life without a genetic mutation. This “acquired hemophilia” occurs when the immune system attacks clotting factors. It may be associated with:

• pregnancy
• autoimmune diseases
• cancer
• certain medications

Symptoms and signs

Common symptoms

Hemophilia symptoms vary by severity:

• unexplained bleeding from minor cuts or abrasions that lasts much longer than usual
• heavy or prolonged bleeding after surgery or dental work
• frequent, large, or deep bruises without obvious injury
• unusual bleeding after vaccination or blood draw
• swelling, pain, or stiffness of joints (from internal joint bleeding)
• blood in urine (dark to cola‑colored) or stool
• frequent nosebleeds without a clear cause
• unexplained irritability in infants
• spontaneous bleeding without a trigger (in severe forms)

Bleeding into joints

One of the most common problems in hemophilia is joint bleeding (hemarthrosis). It most often affects:

• knees
• ankles
• elbows
• shoulders
• hips

When blood accumulates in a joint, it causes:

• swelling and warmth of the joint
• severe pain with joint movement
• reduced ability to bend or straighten the joint

The real danger is repeated bleeding into the same joint, which can cause permanent damage over time. Blood triggers inflammation, and chronic inflammation destroys cartilage inside the joint. Over years this can lead to arthritis or even complete joint destruction, significantly limiting mobility.

That is why modern treatment focuses on prevention—preventing bleeding is far better than treating it later.

Bleeding into muscles

When blood collects inside a muscle (an intramuscular hematoma), it can cause:

• swelling that gradually worsens
• severe pain
• pressure on nerves with resulting numbness or weakness
• possible limb damage if treatment is not prompt

Bleeding into vital organs

Bleeding in the throat/neck, abdomen, or chest is particularly dangerous because it can:

• impair breathing or swallowing
• damage internal organs
• quickly become life‑threatening

Bleeding into the brain (intracranial hemorrhage)

Although rare, bleeding into the brain is among the most serious complications. In someone with severe hemophilia, even a minor head injury can potentially cause brain bleeding.

Warning signs include:

• severe, persistent headache
• repeated vomiting
• sleepiness or difficulty staying awake
• confusion or difficulty concentrating
• blurred or double vision
• sudden weakness or clumsiness
• seizures

Bleeding into the brain is a medical emergency. If any of these signs appear, seek immediate medical help.

When to seek urgent care

Seek help immediately if:

• heavy bleeding does not stop even with pressure
• there are any signs of head injury or brain bleeding (see above)
• you have chest or abdominal pain
• you have difficulty breathing or swallowing
• a joint is significantly swollen, hot, and very painful
• you have severe pain anywhere that does not improve with rest and cooling

How diagnosis is made

Blood tests

Hemophilia is diagnosed with specialized blood tests:

Clotting time tests: Measure how long it takes blood to clot. In hemophilia, clotting is significantly prolonged.

Factor levels: Blood tests measure the exact amount of clotting factor VIII or IX. This determines both the type and severity of hemophilia.

Inhibitor testing: Determines whether the immune system has developed antibodies against clotting factors—an important complication to understand (see below).

Genetic testing

DNA testing can identify the specific mutation causing hemophilia. It helps with:

• confirming the diagnosis
• understanding inheritance for family planning
• estimating hemophilia severity
• genetic counseling for relatives

Prenatal diagnosis

If hemophilia runs in the family, it can be detected during pregnancy using:

• chorionic villus sampling (CVS) – 10–13 weeks of pregnancy
• amniocentesis – 15–20 weeks of pregnancy
• cell‑free fetal DNA testing – can determine the baby’s sex, which is useful because hemophilia most often affects boys

Imaging tests

If internal bleeding is suspected, doctors use ultrasound or MRI to locate the bleeding in the body.

Treatment options

Treatment goal

Hemophilia treatment aims to replace the missing clotting factor so blood clots normally. There are two main approaches:

Prophylaxis (prevention): Regular scheduled treatment to prevent bleeding before it happens. It is like taking vitamins daily to avoid deficiency.

On‑demand treatment: Treatment given after bleeding occurs or before a planned procedure.

Modern medicine strongly recommends prophylaxis, especially for children with severe hemophilia, because preventing bleeding is far better than treating it after the fact.

Clotting factor replacement therapy

This is the main treatment for hemophilia. The missing clotting factor is replaced with a laboratory‑made (recombinant) or donor‑derived version.

How it is given: Factor replacement is administered intravenously. In young children, a small permanent port (central venous access) may be placed to simplify administration.

Home treatment: Families learn to give injections at home, which is far less burdensome than frequent hospital visits.

For hemophilia A: Factor VIII lasts 8–12 hours in the body, so prophylaxis typically requires 2–3 injections per week.

For hemophilia B: Factor IX lasts longer (18–24 hours), so fewer injections are needed.

Newer non‑factor therapies

In recent years, a new treatment called emicizumab (Hemlibra®) has become available. Instead of replacing the missing factor, it restores its function.

Advantages:

• administered by subcutaneous injection (easier than IV)
• dosing once weekly, every two weeks, or monthly depending on dose
• no need for venous access
• approved for severe hemophilia A with and without inhibitors
• recently approved for moderate hemophilia A as well

Other non‑factor therapies are in development and will expand treatment options in the coming years.

Supportive treatment

DDAVP (desmopressin): In people with mild hemophilia, this drug can stimulate the body’s own factor production. It is often used before surgery or dental work.

Tranexamic acid: This drug helps prevent clots from breaking down too quickly. It is useful for minor bleeding or bleeding from the mouth.

Physiotherapy: After bleeding, especially into a joint, physiotherapy helps restore normal movement and prevent permanent damage. It includes exercises, stretching, and sometimes braces or splints.

Medications to avoid

People with hemophilia should NOT take ibuprofen, aspirin, or other NSAIDs (non‑steroidal anti‑inflammatory drugs). These medicines impair clotting and increase bleeding risk.

Use paracetamol (acetaminophen) for pain or fever instead.

Complication – inhibitors

In about 25–30% of people with severe hemophilia A and 3–5% with hemophilia B, a serious complication can arise: the immune system develops antibodies against the replacement clotting factor.

When this happens (so‑called inhibitor development):

• replacement factor is less effective or completely ineffective
• higher doses are needed
• other medicines must be used (so‑called bypassing agents)
• treatment becomes more complex and expensive

Regular blood tests monitor for inhibitors so doctors can adjust treatment as needed.

Complications

Joint damage (hemophilic arthropathy)

Repeated joint bleeding is the most common long‑term problem in hemophilia. The process is as follows:

1. blood accumulates in the joint
2. this causes inflammation (swelling, warmth, pain)
3. blood contains iron, which triggers further inflammation
4. chronic inflammation damages cartilage inside the joint
5. over years this leads to arthritis and can even cause permanent joint destruction

That is why modern prophylactic treatment is so important—preventing bleeding is the best way to protect joints.

Infections related to blood products

Historically, some people with hemophilia who received clotting factor from donated blood were exposed to viral infections including HIV and hepatitis C. In the 1980s and 1990s this was a major tragedy.

Modern safety measures include:

• careful screening of blood donors
• viral inactivation processes that destroy viruses in donated products
• recombinant (laboratory‑made) clotting factors that do not use human blood

The risk of infection from modern clotting factors is extremely low.

Liver disease

People who received contaminated blood products in the past may have chronic hepatitis C or B. This can lead to:

• cirrhosis (liver scarring)
• liver cancer (hepatocellular carcinoma)

Regular liver function tests and monitoring are important for people with hemophilia.

Osteoporosis

Some people with hemophilia have weakened bones (osteoporosis) due to:

• reduced physical activity because of joint problems
• chronic inflammation
• effects of certain medications

Psychological impact

Living with a chronic bleeding disorder can be emotionally challenging. People with hemophilia may experience:

• anxiety about bleeding
• frustration about activity limitations
• concerns about the need for regular treatment
• fear of complications

Support groups, counseling, and connecting with other people with hemophilia can be very helpful.

Understanding treatment – summary

This section summarizes why hemophilia treatment is necessary, how it works, and why it should be individualized.

• Hemophilia slows clotting due to missing clotting factors; treatment replaces the missing factor.
• Without treatment, bleeding can occur into joints, muscles, and vital organs.
• Repeated joint bleeding can lead to chronic damage, arthritis, and reduced mobility.
• The goal of treatment is to reduce the frequency and severity of bleeding and limit long‑term consequences.
• Every bleed should be treated as early as possible to prevent recurrence and worsening joint damage.
• The treatment plan should be individualized and adapted to lifestyle.
• Pharmacokinetics helps estimate drug levels over time and tailor treatment.
• Doses and regimens may change based on age, activity, or planned procedures.

World Federation of Hemophilia (WFH) – an international organization providing guidelines, education, and support for hemophilia worldwide. Website: wfh.org

The Haemophilia Society (UK) – provides support, information, and advocacy for people with hemophilia in the United Kingdom. Website: haemophilia.org.uk

Treatment options – summary

This section summarizes the main types of hemophilia treatment and practical principles for their use.

Replacement therapy (factor replacement)

• The most common treatment replaces the missing factor VIII (hemophilia A) or factor IX (hemophilia B).
• It is administered intravenously; factors can be plasma‑derived or recombinant.
• It can be used prophylactically (prevention) or “on demand” for acute bleeding.
• Prophylaxis is recommended because of lower bleeding risk and joint protection.

Standard and extended half‑life factors

• SHL (standard half‑life) requires more frequent dosing depending on hemophilia type and need.
• EHL (extended half‑life) lasts longer and allows longer intervals between doses.
• EHL treatment can improve adherence, quality of life, and protection against bleeding.
• Half‑life extension is achieved through various technologies (e.g., fusion, pegylation).

Inhibitors and bypass therapy

• Some patients develop antibodies against factors (inhibitors).
• In these cases, bypassing agents or therapies that mimic factor function are used.

Additional options

• Antifibrinolytics help stabilize the clot.
• Tissue adhesives support healing (often in dentistry).
• Vaccination and infection prevention are important for patients receiving blood products.
• Physiotherapy and bleeding prevention help with pain and joint protection.

Self‑administration and long‑term care

• For moderate and severe hemophilia, self‑administration is often recommended.
• Independence supports self‑reliance and the ability to plan life on one’s own terms.
• It is important to always have factor available in case of sudden bleeding.
• An individualized plan and understanding factor levels help safer daily activity.

National Organization for Rare Disorders (NORD) – a U.S. organization offering information and assistance to patients with rare diseases including hemophilia. Website: rarediseases.org

Hemophilia treatment centers – specialized centers with a multidisciplinary team (doctors, nurses, physiotherapists, social workers) experienced in hemophilia care. In most countries these centers exist.

Changing treatment – summary

This section summarizes when and how treatment can be changed and why cooperation with a doctor is important.

• Choosing treatment is a key decision and should always be discussed with a doctor.
• You are not on your first treatment forever; most patients change treatment during life.
• Current data do not show significant safety risks when switching between factors.
• After a change, monitoring is recommended due to possible inhibitor development.
• Inhibitor risk depends on multiple factors and is not just about switching treatment.
• If you are considering a change, address it early with a hematologist who will assess benefits and set a safe plan.
• Medicinal products go through strict approval processes and long‑term safety monitoring.

Where to find support

Doctor visit – summary

This section summarizes how to use cooperation with a doctor and physiotherapist to better manage hemophilia.

• Doctors and physiotherapists help set treatment, sports activities, and work plans.
• Maintain regular contact and ask anything you are curious about.
• Set personal goals (work, sports, travel) and discuss them with your doctor.
• Discuss barriers and concerns that keep you from higher ambitions.
• Create a long‑term plan (e.g., 5 years) and a path to reach it.
• Look for treatment options that make everyday life easier and support your goals.

---

• patient support groups – connecting with other people with hemophilia
• counseling and mental health services – support for psychological aspects of living with hemophilia
• financial assistance programs – help with treatment costs for those who need it
• education programs – for patients and families to better understand the condition and manage it

Living with hemophilia

Normal life expectancy

With proper treatment and care, people with hemophilia have a normal life expectancy. They can:

• go to school and work
• have a family and relationships
• pursue most hobbies and interests
• live independently in adulthood

Physical activity

Suitable activities:

• swimming and water sports (excellent for joint health)
• cycling (with protective gear)
• walking and light running
• tennis, badminton, bowling
• most recreational activities with low risk of injury

Activities to avoid or limit:

• contact sports (football, rugby, boxing, hockey)
• motorsports
• activities with a high risk of falls (climbing, skateboarding)
• activities with a risk of head injury

The key is to find balance—stay active and healthy while minimizing injury risk.

School and work

Most students with hemophilia attend regular schools and choose standard career paths. Some considerations:

• teachers and employers should know about hemophilia
• accommodations may include avoiding heavy lifting or certain physical tasks
• career choice may be influenced by physical demands
• many successful professionals have hemophilia

Relationships and family planning

People with hemophilia can have relationships, marry, and have children. Important notes:

• genetic counseling before planning children helps understand inheritance risk
• for women: pregnancy requires special planning and care. Factor VIII levels often rise during pregnancy, which is protective, yet careful obstetric care is still needed
• partners should be informed about hemophilia
• modern treatment makes managing pregnancy with hemophilia much safer than in the past

Medical care and monitoring

People with hemophilia need lifelong health care, including:

• regular visits to a hemophilia center
• regular blood tests to monitor factor levels and inhibitor development
• physical examinations, especially of joints
• physiotherapy checkups to maintain joint and muscle function
• dental care with hemophilia in mind

Transition to adulthood

As children grow up, they gradually take on more responsibility for managing hemophilia:

• learning self‑administration of injections
• understanding their own health needs
• making informed treatment decisions
• managing appointments independently
• transitioning from pediatric to adult hemophilia care

Safety measures

• Medical identification: Wear a medical bracelet or pendant that states hemophilia. In an emergency this alerts healthcare providers to the diagnosis.
• Inform healthcare providers: Always tell doctors, dentists, and other providers about hemophilia, especially before procedures.
• Emergency plan: Know where the nearest emergency department is and have a plan to obtain hemophilia treatment quickly.
• Record keeping: Keep records of the type and level of clotting factor.

Surgery and dental procedures

Any surgical or dental procedure requires special planning:

• inform the hemophilia center well in advance
• increased factor coverage is needed before, during, and after the procedure
• all involved healthcare providers must be aware of hemophilia
• coordination between the hemophilia center and surgical team is essential

---

From dreams to experiences – summary

The following summary is based on texts about daily life with hemophilia, family experience, and treatment history. It focuses on key ideas and practical insights.

Hemophilia in the family – generations without barriers

• Hemophilia affects the whole family, but today it is no longer the center of family life.
• Initial emotions are mixed (fear, uncertainty, questions), gradually replaced by understanding the care system.
• Families gain confidence through clear procedures, specialized centers, and accessible treatment.
• Home treatment brings calm, more independence, and the ability to adapt the routine to family life.
• Sibling relationships are more balanced; children often function as a team and have more space for their own life.
• The family atmosphere is calmer: more planning, less fear, more normal activities and travel.

Life with hemophilia – challenges and victories

• In the past, hemophilia meant social restrictions; today most people plan life on their own terms.
• At school, awareness and planning are important, not bans on activities.
• Childhood: formerly constant vigilance, today more organization and agreements instead of prohibitions.
• Adolescence brings questions about confidence and openness; modern treatment provides greater security.
• Key skill: planning treatment and workload (when to administer treatment, how to pace training, what to monitor after activity).
• In adulthood, responsibility, planning, and control over treatment are key.
• Hemophilia remains part of life, but no longer defines it.

Treatment history – a path of hope

• In the past, hemophilia was life‑threatening and treatment almost nonexistent.
• Historical mentions point to mother‑linked inheritance; hemophilia was known as the “royal disease.”
• Without treatment, even minor injury meant high risk; common childhood activities were practically impossible.
• The 20th century brought blood transfusions and plasma factors—the first major breakthrough.
• In the 1970s–80s, treatment availability was limited and home administration was rather exceptional.
• The 1980s brought a tragic period of infections from blood products (HIV, hepatitis).
• Today means prophylaxis, home treatment, and modern recombinant and long‑acting products.
• Current care enables an almost full life and a shift in social perception of hemophilia.

Level of protection – what affects bleeding risk

• The level of protection depends on the blood level of clotting factor.
• Factor level determines hemophilia severity and symptom intensity.
• Normalized hemostasis means levels similar to a person without hemophilia.
• Normalized hemostasis is considered levels above 40%.
• Higher levels can reduce the risk of joint bleeding, support joint health, and improve quality of life.
• The key is open communication with the doctor and setting personal goals and a protection plan.

Links to the original articles

• Hemophilia in the family – generations without barriers
• Life with hemophilia – challenges and victories
• Treatment history – a path of hope
• Level of protection

---

Practical tips – joint bleeding

This section summarizes practical information on recognizing joint bleeding and the first steps that help protect the joint from further damage.

How to recognize joint bleeding and why acting early matters

• Joint bleeding is among the most common complications of hemophilia.
• It most often affects elbows, knees, and ankles.
• Repeated bleeding leads to chronic inflammation and cartilage damage (hemophilic arthropathy).
• Typical symptoms: an unusual feeling in the joint (pressure, tingling), pain, swelling, limited mobility, increased skin temperature, sometimes redness.
• Experienced patients often recognize bleeding by early signals; in unclear cases ultrasound helps.
• Early treatment is crucial, because each further bleed can further damage the joint.

All about hemophilia

Quick overview and navigation to detailed sections of the page (to avoid repeating the same information).

• What is hemophilia – basic definition and principles.
• Types of hemophilia – A/B and severity.
• Inheritance – X‑linked genetics.
• Treatment – prophylaxis, factor and non‑factor therapy.
• Complications – joints, inhibitors, infections.

---

Keep pain under control – summary

This section summarizes recommendations for managing pain and caring for joints in hemophilia.

• Joint bleeding can cause pain, limited movement, and frustration.
• Treatment choice should match lifestyle; if bleeding signs appear, it is important to contact a hematologist.
• Physiotherapy helps restore mobility and provides relief even with long‑term pain.
• It is helpful to learn simple home exercises and perform them regularly.
• Regular, appropriate movement strengthens joints and muscles and reduces pain risk.
• If injury or worsening occurs, it is crucial to quickly contact the treating physician.
• Understanding types of pain helps better manage its impact on daily life.

---

Technologies such as CRISPR‑Cas9 could directly edit faulty genes in a patient’s cells and correct the mutation. This is still an early research phase, but it represents another possible path to curing hemophilia.

New non‑factor therapies

Exercise and joint health – summary

This section summarizes the importance of movement for people with hemophilia, recommendations for safe exercise, and prevention of joint problems.

Why exercise is important

• Regular movement improves fitness, self‑confidence, and reduces the risk of cardiovascular disease, diabetes, and osteoporosis.
• In hemophilia, it strengthens muscles, stabilizes joints, and reduces bleeding and damage risk.
• It is advisable to consult exercise plans with a doctor or physiotherapist.

Home exercise and physiotherapy

• Joints are more prone to bleeding, so a combination of movement and targeted physiotherapy is recommended.
• Regular home exercises help maintain joint strength and mobility.
• Proper care after bleeding and consistent stretching reduce the risk of stiffness and complications.

How to choose sport and plan workload

• Avoid intense contact sports; safer are non‑contact activities (swimming, cycling, badminton, walking).
• Adapt activity to your current fitness and health status.
• Plan infusion timing with the demands of the sport in mind.
• Warm‑up and post‑exercise stretching are essential for injury prevention.

Practical principles

• Do not exercise through pain; if bleeding is suspected, contact your doctor.
• Progress gradually and avoid overexertion.
• Find a rhythm and regularity that is sustainable long‑term.

---

In addition to emicizumab, pharmaceutical companies are developing other non‑factor therapies that work differently and may bring additional benefits.

Artificial clotting factors

Work and career – summary

This section summarizes how modern treatment expands work opportunities and how to think about sharing the diagnosis at work.

• Modern treatment allows people with hemophilia a wider choice of job opportunities than before.
• In the past, frequent bleeding and hospitalizations limited careers; today people have more options.
• The decision whether to disclose hemophilia at work is individual and depends on the job and personal comfort.
• With mild forms, it may be possible not to mention the condition at first; later you can explain the situation to colleagues.
• If hemophilia significantly interferes with work, discuss it with a doctor.
• Employers must not discriminate because of hemophilia; health questions must be relevant to the job.
• Prophylaxis enables some previously inaccessible fields, though some professions remain risky.
• Real options are often broader than they first appear if risks are well managed.

---

Scientists are working on fully synthetic, artificial clotting factors made in the lab. The advantage would be products that do not trigger immune reactions (no inhibitors) and are consistent and safe.

---

Traveling with hemophilia – summary

This section summarizes how to safely plan travel with hemophilia.

• Thanks to prophylactic treatment, travel is possible as freely as for others.
• Preparation is best divided into three steps: consultation, planning, packing.
• Before booking a trip, consult the plan with your doctor and obtain necessary documents.
• Make sure you will be able to store medicines properly (e.g., a fridge at your accommodation).
• Find contacts for hemophilia centers in the destination country in advance.
• When packing, do not forget medicines, supplies, and documents including insurance.

---

I am a parent of a young child with hemophilia

This section summarizes key recommendations for parents and caregivers of young children with hemophilia, including balancing protection and normal life.

Life almost like everyone else

• The hardest part is setting boundaries so the child can explore the world while staying safe.
• Adolescents gradually take responsibility for their own treatment, which can be a challenging period for parents.
• Hemophilia is chronic, but with proper treatment and care it is possible to live fully.
• Care is more frequent at first; over time check‑ups stabilize at the necessary minimum.

Balance between protection and possibilities

• The goal is not to restrict the child, but to protect them while supporting independence.

Protection

• Establish a regular treatment routine from the beginning.
• Adapt the home for safety (edge guards, barriers, safety devices).
• Maintain oral hygiene and prevent dental procedures.
• Always coordinate intramuscular injections with a doctor and note hemophilia.
• Avoid medications that worsen clotting; consult suitable medications with a hematologist.

Involving healthcare providers

• Inform the dentist, pediatrician, and other doctors about the diagnosis.
• Provide the child with an identifier listing the diagnosis, blood type, medications, and doctor contact.
• In case of concerns, contact a specialized center.

Opportunities and activity support

• Physical activity helps strengthen muscles and joints; treatment dosing can be adjusted by agreement.
• Appropriate treatment enables participation in normal activities; restrictions apply mainly to contact sports.
• Encourage the child to gradually master self‑injections and take an active role in treatment.
• Regular movement and group activities improve fitness and mental well‑being.

---

I am a young person with hemophilia

This section summarizes topics of adolescence and entering adulthood, when independence and responsibility for treatment increase.

Adolescence and independence

• The period of adolescence brings new beginnings (school, moving, independence) and more responsibility.
• You need to take over treatment care: checkups, ordering medicines, keeping records, and communicating with doctors.
• At first it can be challenging, but it gradually becomes routine.
• Proper support and information can make adolescence a positive and enriching time.

Find your own balance

• Life with hemophilia can be mentally demanding due to planning, treatment, and social pressure.
• The key is to find a balance between protecting health and freedom in activities.

When to tell others

• It is natural to hesitate about whom and when to tell about hemophilia.
• It is useful for people who can help to know (school, close friends).
• The announcement does not have to be dramatic—often a simple explanation and myth‑busting is enough.

Relationships and intimacy

• Sex life is a normal part of life with hemophilia; questions should be discussed with a doctor or trusted health professional.
• When disclosing the diagnosis to a partner, simple questions help: when is the right time, how to explain it, and how to answer questions.
• It can be helpful to talk with someone more experienced from the hemophilia community (online or in person).

---

I am a senior with hemophilia – summary

This section summarizes how hemophilia care changes with age and why increased medical cooperation is important.

• In recent decades, hemophilia treatment has advanced greatly and quality of life has improved.
• In seniors, conditions related to aging are considered alongside hemophilia.
• Aging brings similar changes as in others, but some risks may be higher for people with hemophilia.
• To maintain the best possible health, a responsible approach and regular medical oversight are important.
• Individualized treatment makes it possible to live actively and fully even in senior years.

---

Current status: Gene therapies are in advanced clinical trials. Some patients have achieved remarkable results and near‑normal factor levels after a single treatment. The question of how long the effect lasts is still being studied.

Challenges: Gene therapy is extremely expensive (potentially USD 2–3 million per treatment), and long‑term safety data are still being collected. For many patients, however, it represents hope for a possible cure.

Hemophilia in adulthood – summary

This section summarizes how modern treatment affects the lives of adults with hemophilia, including long‑term complications and needs in working and senior years.

Working‑age adults

• Modern treatment and prophylaxis help prevent worsening health issues and extend life expectancy.
• Adults can travel, work, have families, and pursue hobbies much like others.
• Support can come from family, friends, and patient organizations.
• A frequent issue is joint damage from earlier treatment eras; current products reduce the risk of further bleeding and slow deterioration.
• Some people were exposed in the past to infections from blood products (hepatitis, HIV) and may need additional treatment.

Seniors and comorbidities

• Today’s seniors with hemophilia reach ages close to the general population.
• With age, conditions such as hypertension, diabetes, cardiovascular and oncologic diseases increase.
• People with past viral infections may develop liver disease.
• The treatment goal is the same as for other seniors: maintain the highest possible quality of life for as long as possible.

What can improve quality of life

• Prophylaxis and the option for home administration significantly increase comfort and freedom.
• Longer‑acting treatment would allow longer intervals between doses.
• Tools for reminders and treatment tracking can help.
• Information about centers abroad and travel options with hemophilia is also useful.

---

Extended half‑life products

Newer clotting factors were designed to last 1.5 to 3 times longer than traditional factors. This means:

Childhood and adolescence with hemophilia – summary

This section summarizes care specifics from early childhood to adolescence, including diagnosis, school environment, and family needs.

Diagnosis and the first years

• In the Czech Republic, a small number of boys are born each year with hemophilia; some cases arise from new mutations.
• In carriers, diagnosis may be known during pregnancy or after umbilical cord blood testing.
• In children without family history, hemophilia often appears in the 1st–2nd year of life (bruises, hematomas, bleeding when teeth erupt).
• A simple clotting test (aPTT) can speed diagnosis when bleeding is unusual.

Infants, toddlers, and younger preschoolers

• Families have frequent visits to hemophilia centers where severity is established and IV administration training is provided.
• The period can be psychologically and practically demanding; early psychological support is important.
• Modern, safe, and precisely dosed treatment enables life close to normal.

Older preschoolers and school‑age children

• The child learns to live with the condition and perceives certain restrictions (e.g., contact sports).
• Uncertainty and misunderstanding at school can lead to feelings of being different.
• Education of teachers helps overcome barriers and adapt activities.
• Modern treatment broadens the spectrum of activities including school trips.
• Camps and events for children with hemophilia support independence and experience with treatment.

Adolescence

• Questions increase about sharing the diagnosis, relationships, and career choice.
• Defiance and risk behavior can worsen adherence, but can be managed with proper support.

What could help families

• Better support in recognizing bleeding (e.g., 24/7 consultation).
• Longer‑acting medications for longer intervals between doses.
• Tools for reminders and treatment tracking.
• More information about centers abroad and traveling with hemophilia.

---

• fewer injections (possibly only once or twice a week)
• less disruption of everyday life

Hemophilia and mental well‑being – summary

This section summarizes practical tips on strengthening mental well‑being while living with hemophilia.

• Mental well‑being is as important as physical health.
• Warning signs of worsening mental health can include low mood, loss of interest, inability to relax, sleep problems, or difficulty concentrating.
• It helps to share worries with a partner, family, friends, or a doctor and ask for specific help.
• Pain, bleeding, or demanding treatment can worsen mental health; discuss treatment adjustments with a hematologist.
• Negative thought spirals can be interrupted with mindfulness and a critical look at one’s thoughts.
• Small joys and regular favorite activities support a stable mood.
• Self‑care (movement, diet, sleep) significantly affects mental well‑being.
• Avoid relying on alcohol or addictive substances; seek professional help if needed.
• Do not be afraid to ask for help; in acute situations you can use crisis hotlines.

---

• better treatment adherence

Gene editing

Covid‑19 and hemophilia – webinar summary

This section summarizes the main recommendations from a webinar on covid‑19 and hemophilia.

• Hemophilia itself does not increase the risk of a more severe course of covid‑19 compared to the general population.
• SARS‑CoV‑2 is not proven to be transmissible by blood; recombinant factors pose no transmission risk.
• Do not stop prophylaxis; regular treatment is crucial.
• Stay physically active even during restrictions.
• Keep a small reserve of medications to reduce trips to the pharmacy.
• Risk of a severe course is mainly for people over 60 and those with other illnesses.

Basic preventive measures

• Limit social contact and keep safe distance.
• Wear face protection outside the home.
• Maintain hand hygiene and avoid touching your face.
• If in contact with an infected person, follow quarantine.
• Prefer phone or email consultations with healthcare providers.
• Schedule an exact time for center visits to minimize waiting.
• If you have trouble picking up medications, delivery through patient organizations may be available.
• Urgent and necessary procedures take place under the supervision of a hemophilia center.

---

• online communities – virtual support and information sharing

Main resources

Glossary of terms – summary

A concise overview of basic terms used in hemophilia care.

Bleeding and joints

• Hemarthrosis – blood in a joint.
• Hemorrhage – the medical term for bleeding.
• Epistaxis – nosebleed.
• Hematuria – blood in urine.
• Arthritis – joint inflammation with pain and limited movement.
• Arthropathy – a collective term for joint disease.
• Arthroplasty – reconstructive joint surgery.
• Target joint – a joint with recurrent bleeding and insufficient healing.
• Spontaneous bleeding – bleeding without an obvious cause, typical for severe forms.
• Thrombus – a blood clot in a vessel or the heart.

Blood clotting and laboratory tests

• Coagulation – the process of blood clotting.
• Hemostasis – the set of processes that stop bleeding.
• Clotting factor – proteins involved in blood clotting.
• aPTT – a clotting test (activated partial thromboplastin time).
• Quick test / prothrombin time – another blood clotting test.
• Coagulation parameters – laboratory indicators of clotting.
• Coagulopathy – a clotting disorder due to factor deficiency or inhibitors.
• Fibrin / fibrinogen – proteins essential for clot formation.
• Thrombocyte – platelet.

Types of hemophilia and severity

• Hemophilia – inherited clotting disorder.
• Hemophilia A – factor VIII deficiency.
• Hemophilia B – factor IX deficiency.
• Mild / moderate / severe hemophilia – based on factor level in blood.
• Acquired hemophilia – develops during life due to inhibitors.
• Bleeding phenotype – individual bleeding tendency with similar factor levels.

Treatment and regimens

• Replacement therapy – supplementing the missing factor.
• Prophylaxis – regular preventive factor administration.
• On‑demand – giving factor only during bleeding.
• Bypassing agent – treatment that bypasses blocked factors in inhibitors.
• Antifibrinolytics – drugs that stabilize a blood clot.
• Plasma‑derived / recombinant factor – origin of the factor (plasma vs. lab‑made).
• SHL / EHL factor – standard vs. extended half‑life.
• Fc fusion / albumin fusion / pegylation – technologies that extend factor activity.
• Half‑life – time for factor level to drop by half.
• Pharmacokinetics / PK curve – drug levels over time for personalized dosing.
• Immune tolerance therapy – attempt to “teach” the body to stop inhibitors.
• Inhibitor of clotting factor – antibody that blocks factor action.
• Intravenous / subcutaneous administration – method of drug delivery.
• Adherence – degree of compliance with treatment.

Other terms

• Anemia – low hemoglobin.
• Gene therapy – treatment aimed at correcting the genetic cause.

This material is based on information from:

• World Federation of Hemophilia Guidelines for the Management of Hemophilia (3rd edition, 2020)
• National Organization for Rare Disorders (NORD) Rare Disease Report on Hemophilia A (2025)
• educational materials from The Haemophilia Society
• clinical information from Great Ormond Street Hospital NHS Foundation Trust
• medical information from Mayo Clinic
• current peer‑reviewed medical literature and research

Future treatment and research

Gene therapy

One of the most exciting areas of hemophilia research is gene therapy. The idea is revolutionary: instead of repeatedly replacing the missing factor with injections, why not fix the genetic problem itself?

How it works:

1. scientists use a modified virus as a “carrier” to deliver a correct copy of the gene into the body
2. the virus enters cells (usually liver cells), where clotting factors are produced
3. the cells now have the correct genetic instructions
4. the cells begin producing normal clotting factor
5. the person no longer needs regular factor injections

Current status: Gene therapies are in advanced clinical trials. Some patients have achieved remarkable results and near‑normal factor levels after a single treatment. The question of how long the effect lasts is still being studied.

Challenges: Gene therapy is extremely expensive (potentially USD 2–3 million per treatment), and long‑term safety data are still being collected. For many patients, however, it represents hope for a possible cure.

Extended half‑life products

Newer clotting factors were designed to last 1.5 to 3 times longer than traditional factors. This means:

• fewer injections (possibly only once or twice a week)
• less disruption of everyday life
• better treatment adherence

Gene editing

Technologies such as CRISPR‑Cas9 could directly edit faulty genes in a patient’s cells and correct the mutation. This is still an early research phase, but it represents another possible path to curing hemophilia.

New non‑factor therapies

In addition to emicizumab, pharmaceutical companies are developing other non‑factor treatments that work differently and may bring additional benefits.

Artificial clotting factors

Scientists are working on fully synthetic, artificial clotting factors made in the lab. The advantage would be products that do not trigger immune reactions (no inhibitors) and are consistent and safe.

Notice

This website is for educational purposes only. It does not replace professional medical advice, diagnosis, or treatment. If you have questions about hemophilia or your health, contact a qualified healthcare professional or hemophilia specialist.

Information on this website was current as of February 2026. Medical knowledge evolves, so always seek the most up‑to‑date professional guidance.

Last updated: February 2, 2026